This study evaluated adherence rates and health outcomes across three academic centers with integrated specialty pharmacies. Centers with specialty pharmaies had high medicaiton possession ratio (MPR). Self-injectable biologic therapy non-adherence was associated with higher likelihood of emergency department visits and hospitalizations.

This study evaluated the impact of delayed insurance approval on outcomes in patients prescribed alternate doses of biologic therapy for the treatment of IBD. Researchers found that longer time to insurance approval of a higher biologic dosing regimen was associated with an increase in C-reactive protein, an inflammatory marker, in at least 45 days after the decision to escalate dose, suggesting the longer time to approval, the less likely to see an improvement in C-reactive protein.

The objective of this study was to evaluate if medication non-adherence is associated with increased healthcare resource utilization. In patients with moderate-to-severe IBD on self-injectable biologic medication, non-adherence (MPR 0.86) is associated with increased risk of hospitalization and emergency department visits.

This article discusses development of a quality measures tool to track outcomes for self-injectable biologic therapy used in the management of inflammatory bowel disease. Through a collaborative initiative, a set of clinical and specialty pharmacy quality measures was developed to assess outcomes such as patient safety, disease status, treatment efficacy, and healthcare resource utilization.

The purpose of this study was to assess medication non-adherence [defined as medication possession ratio (MPR)]and validate the findings of risk factors for non-adherence to biologic therapy for adult inflammatory bowel disease: narcotic use, psychiatric diagnosis history, prior biologic use, and smoking. This study found that previously identified cumulative risk factors remain significant.

This study retrospectively reviewed adherence and real-world outcomes of inflammatory bowel disease patients who initiated tofacitinib at a single care center. Sixty-three patients were identified. All patients failed at least on prior biologic therapy. Mean proportion of days covered was 95.7% for ulcerative colitis and 93.1% for Crohn's disease. Significant clinical and endoscopic response was seen. Adherence was high in a cohort with high refractory disease.

This poster evaluates patient characteristics and 3-month outcomes in patients prescribed alternate-dose biologic therapy. Of 220 patients, one-third were previous/current smokers, and 40% had a psychiatric comorbidity. Median disease duration was 11 years (IQR 6-18), 46% previously underwent surgery.

This study evaluated access and affordability of HIV PrEP in patients seen at a multidisciplinary PrEP clinic. In this cohort of mostly commercially insured men, the majority were able to access PrEP with low out-of-pocket costs facilitated by manufacturer assistance. Although generalizability beyond this population is limited, these results contradict perceived financial barriers to PrEP access.

In the Southern US, HIV prevalence is disproportionately high and PrEP use is disproportionately low. This cross-sectional survey study assessed Tennessee primary care providers’ current PrEP knowledge, attitudes, and prescribing practices with the aim to determine barriers to PrEP provision specific to TN providers.

The purpose of this study was to explore student education about HIV and related topics using a cross-sectional, population-based survey of U.S. pharmacy schools with a 15-item questionnaire. We found diversity in the amount of time devoted to HIV didactic education among the 37 U.S. pharmacy schools who completed the survey, with some schools providing minimal didactic teaching on the topic of HIV along with low rates of exposure to PLWH in experiential training.